Learn Mode

LLY - Eli Lilly and Co

514

$954.52

$34.75 (3.778%)

At market close

$956.63

$2.11 (0.221%)

After Hours 4/1/26, 10:30 PM

Score

4.56/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

LLY

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$906.70B

Industry

Pharmaceuticals

EPS (TTM)

$22.98

P/E (TTM)

43.93

Div & Yield

$6.92 (0.72%)

FCF Payout Ratio

110.22%

P/S (TTM)

13.91

P/B

34.17

Diluted Shares

898.00M

Ex-Dividend

2026-02-13

Next Earnings

04-30

Forward P/E

25.89

Payout Ratio

31.85%

P/FCF (TTM)

152.03

FCF Yield

0.66%

Earnings Yield

2.28%

52 Week Range

Score Card

Explore Scores Tab

4.56

Very Good

Eli Lilly and Co has grown revenue at 44.7% over the past year, which is strong growth. Also, it has seen its diluted average shares outstanding decrease by -0.56% over the past year, which suggests the company is buying back shares.

Valuation Model

Key Score

3.00

Average

Management

3.00

Average

Growth

3.00

Average

Profitability

5.00

Very Good

Fin. Health

3.00

Average

Dividends

3.00

Average

Analyst

4.00

Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

2 new filings were in the last 7 days

Filter Form Types

Form DFAN14A

Unknown Form Type

Filed on 2026-03-31 08:18:58

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-26 18:02:53

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-03-20 16:23:04

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required